Newsbenzinga
Outlook Therapeutics Eye Drug Review Returns To FDA For Fourth Time
· Published
Article summary
Outlook Therapeutics shares rose after the FDA accepted its resubmitted LYTENAVA BLA and set a July 2026 target action date.
An excerpt from the original article.
Comments —
Loading comments…